RESEARCH – SCIENTIFIC ACTIVITY

1983 - 2006

Traditional medicine based on reductionist biology, genetics, pathology and clinical research focused on components of a system of interest. Fields of interest: Gastric, breast, colorectal cancer.

2007 - today

NETWORKS MEDICINE: Systems biology & and cancer networks approach towards a next-generation of biomarkers and drugs based on beyond genome and cancer genome structure on functional regulatory networks.
From reductionist ‘classical” medicine to innovative networks medicine

1. Publications and citations, h-factor

New algorithm (Ioannina) for improving diagnostics, prevention and treatment of patients with hereditary breast ovarian cancer syndrome.
•  Roukos DH , Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol. 2007 Oct; 4(10):578-90.

Single genes and genetic testing for hereditary and sporadic cancer
•  Roukos DH , Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007 Mar; 6(3):308-12.

Applying high-throughput technologies for gene-expression profiling data derived from microarrays and PCR arrays for identifying gene signatures as biomarkers for personalized cancer care.
•  Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008 Jan; 8(1):29-39.

The innovation lies in the necessity of clinical homogeneous data integration, besides omics data, to approach systems medicine. Such a comprehensive network model may lead to medical implementation
•  Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn. 2010 Jan; 10(1):33-48.

Dynamics of spatiotemporal personal genome-lifestyle interactions network
Major complex diseases, such as cancer, diabetes, neurodegenerative and psychiatric disorders, arise as a result of dynamic long-term individual genome-lifestyle interactions networks. Therefore, applying revolutionary technologies (NGS, WGS, WES, CHIP-seq, RNA-seq), mass spectrometry, living cells imaging using biosensors for visualizing signal transductions interactions networks for generating genomic, proteomic/interactomic, transcriptomic and chromatin-based gene-expression profiling data in dynamic manner [multiple timely (i.e. every 6 months) omics measurements] can reveal pathobiological causal changes in the comprehensive landscape of genomics. This integrative analysis of personal omics profile in combination with clinical data can predict personalized risks of diseases in asymptomatic patients and appropriate preventive medical intervention. Advances in systems computational biology, synthetic biology and mathematical models may predict complex nonlinear networks at molecular (DNA, RNA, genes, proteins, molecules) and whole organism order of magnitude can contribute to the new epoch of systems medicine. Dynamics of a personal genome code.
•  Roukos DH . Spatiotemporal individual genome code - lifestyle network : revolutionizing personal diagnostics . Expert Rev Mol Diagn 2012 Apr; 9(3): 215-218. DOI: 10.1586/ERM.12.7

Healthy longevity by preventing both aging-related diseases (cancer, Alzheimer) and cells-organism aging by modifying cells signalling pathways network.
•  Roukos DH . Longevity with systems medicine? Epigenome, genome and environment interactions network. Epigenomics. 2012 Apr; 4(2):119-23. DOI: 10.2217/EPI.12.1

Next-generation drugs and biomarkers based on physical networks (protein-protein interactions; DNA-binding proteins) and functional networks (gene–gene).
•  Roukos DH . Differential signalling transduction networks for clinical robustness. Expert Rev Proteomics 2012 Apr; 9(2): 111-114. DOI: 10.1586/ERP.12.14.

High-throughput NGS technologies and systems-synthetic biology to recreate genetic code for clinical implications
•  Roukos DH. Biotechnological, genomics and systems-synthetic biology revolution: Redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices 2012 Mar; 9(2): 97-101.

i) Evaluator of research projects with both remote evaluation and active participation in consensus meetings

1. Evaluator in EU research projects (Health-FP7-INNOVATION-1-2-Systems Medicine and Personalized Medicine (2011, 2012, Experts panel consensus meetings, Brussels )

2. Evaluator in France "Agence Nationale de la Recherche" (ANR) research projects (Equipex 2011 ANR 2 Experts panel consensus meetings, Paris 20-21 Sept., and 30 Nov.-2 Dec. 2011), and 4 projects of " Institut National de la Santé et de la Recherche Médicale" (INSERM) of 'Physique-Cancer' Program.

ii) Remote evaluation - Reviewer of national research projects
Reviewer (with honorarium): Research projects from European countries (UK, Italy, The Netherlands) and Asian countries (Singapore, Taiwan, Hong-Kong).